From nano-formulation toward randomized clinical trial of nano-curcumin on multiple sclerosis patients (a pilot study)

Background and Aim: Nano-formulation of herbal active ingredients is a very effective way to increase the efficacy of these treatment methods and optimize them. The purpose of this type of formulation is to increase the effectiveness, permeability to tissue, targeted drug delivery and reduce the dose of the active ingredient, which significantly reduces side effects and duration of treatment. In this study, we formulated the main active ingredient of Curcuma longa (curcumin) as a complete extract to use it as a powerful antioxidant in the treatment of multiple sclerosis patients. The resulting nano-formulation was tested on ۷۰ patients with recurrence and improvement of MS.Methods: We used our nano curcumin (Curcuden®) as ۱ gr soft gelatin capsules each containing ۷۰ mg dendrosomal Turmeric extract.۱۰ RRMS patients were administered with Curcuden®, ۲۱۰ mg/day, andtheir clinical data containing EDSS and MRI were assessed before and after treatment. Also their blood levels of pro and anti-inflammatory cytokines were assessed with real time PCR technique.Results: Our Data revealed that Curcuden® reduces EDSS and formation of new lesions in CNS and alters the profile of cytokines in favor of anti-inflammatory in these patients.Conclusion: This study showed that curcumin nano-formulation can enhance curcumins bioavailability by increasing solubility and thus improves its therapeutic properties such as anti-inflammatory effects and reducing lesions in CNS. This result can be used to help treat most neurodegenerative diseases that result from inflammation of the nervous system.

Keywords:

Nano-formulation , Curcuden® , Multiple Sclerosis.